CORMEDIX INC. (CRMD) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 187.40M USD | Liabilities, Current |
| Cash and equivalents | 256.69M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current |
| Customer receivables | 161.31M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 38.58M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $187.40M | $256.69M | (m) | $161.31M | $38.58M | (m) |
| 2026-03-31 | (m) | $128.78M | $178.09M | (m) | $154.81M | $30.73M | (m) |
| 2025-12-31 | $326.43M | $174.27M | $144.84M | $10.36M | $171.23M | $29.72M | 1.87× |
| 2025-09-30 | $215.16M | $133.64M | $48.49M | $8.09M | $158.57M | $28.92M | 1.61× |
| 2025-06-30 | (m) | $31.71M | $159.31M | (m) | $42.91M | $9.63M | (m) |
| 2025-03-31 | (m) | $34.39M | $66.29M | (m) | $54.61M | $7.49M | (m) |
| 2024-12-31 | (m) | $33.84M | $40.65M | (m) | $51.65M | $7.60M | (m) |
| 2024-09-30 | (m) | $18.48M | $35.29M | (m) | $17.39M | $6.65M | (m) |
| 2024-06-30 | (m) | $11.11M | $28.54M | (m) | $206.34K | $4.01M | (m) |
| 2024-03-31 | (m) | $9.53M | $35.18M | (m) | (m) | $2.32M | (m) |
| 2023-12-31 | (m) | $11.40M | $43.64M | (m) | (m) | $2.11M | (m) |
| 2023-09-30 | (m) | $7.67M | $53.31M | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $7.39M | $19.70M | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $4.67M | $25.27M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $6.31M | $43.15M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $5.06M | $43.25M | (m) | (m) | $269.00 | (m) |
| 2022-06-30 | (m) | $5.27M | $48.93M | (m) | (m) | $1.72K | (m) |
| 2022-03-31 | (m) | $4.29M | $45.39M | (m) | (m) | $2.61K | (m) |
| 2021-12-31 | (m) | $5.35M | $53.32M | (m) | (m) | $3.01K | (m) |
| 2021-09-30 | (m) | $5.21M | $66.32M | (m) | (m) | $48.92K | (m) |
| 2021-06-30 | (m) | $3.12M | $73.09M | (m) | (m) | $72.73K | (m) |
| 2021-03-31 | (m) | $3.05M | $76.21M | (m) | (m) | $85.07K | (m) |
| 2020-12-31 | (m) | $4.16M | $41.91M | (m) | (m) | $143.56K | (m) |
| 2020-09-30 | (m) | $4.60M | $34.36M | (m) | (m) | $200.71K | (m) |
| 2020-06-30 | (m) | $5.71M | $16.49M | (m) | (m) | $277.83K | (m) |
| 2020-03-31 | (m) | $5.80M | $12.20M | (m) | (m) | $294.91K | (m) |
| 2019-12-31 | (m) | $5.83M | $16.35M | (m) | (m) | $338.46K | (m) |
| 2019-09-30 | (m) | $5.01M | $20.15M | (m) | (m) | $381.06K | (m) |
| 2019-06-30 | (m) | $4.35M | $14.56M | (m) | (m) | $402.71K | (m) |
| 2019-03-31 | (m) | $4.33M | $18.26M | (m) | (m) | $419.60K | (m) |
| 2018-12-31 | (m) | $7.77M | $17.62M | (m) | (m) | $428.51K | (m) |
| 2018-09-30 | (m) | $17.55M | $6.44M | (m) | (m) | $341.18K | (m) |
| 2018-06-30 | (m) | $12.40M | $4.70M | (m) | (m) | $672.94K | (m) |
| 2018-03-31 | (m) | $8.77M | $8.16M | (m) | (m) | $578.91K | (m) |
| 2017-12-31 | (m) | $6.26M | $10.38M | (m) | $64.15K | $594.19K | (m) |
| 2017-09-30 | (m) | $4.25M | $5.21M | (m) | (m) | $299.49K | (m) |
| 2017-06-30 | (m) | $5.79M | $7.94M | (m) | (m) | $313.13K | (m) |
| 2017-03-31 | (m) | $3.89M | $6.82M | (m) | (m) | $94.87K | (m) |
| 2016-12-31 | (m) | $4.09M | $8.06M | (m) | $12.01K | $166.73K | (m) |
| 2016-09-30 | (m) | $5.04M | $9.83M | (m) | (m) | $118.21K | (m) |
| 2016-06-30 | (m) | $3.12M | $12.02M | (m) | (m) | $157.50K | (m) |
| 2016-03-31 | (m) | $3.06M | $13.18M | (m) | (m) | $333.87K | (m) |
| 2015-12-31 | (m) | $3.06M | $11.82M | (m) | $315.77K | $376.57K | (m) |
| 2015-09-30 | (m) | $2.88M | $14.25M | (m) | (m) | $699.15K | (m) |
| 2015-06-30 | (m) | $1.91M | $24.11M | (m) | (m) | $715.05K | (m) |
| 2015-03-31 | (m) | $2.12M | $8.80M | (m) | (m) | $461.40K | (m) |
| 2014-12-31 | (m) | $1.43M | $4.34M | (m) | $80.18K | $463.03K | (m) |
| 2014-09-30 | (m) | $1.23M | $5.92M | (m) | (m) | $677.42K | (m) |
| 2014-06-30 | (m) | $1.18M | $7.65M | (m) | (m) | $278.05K | (m) |
| 2014-03-31 | (m) | $1.12M | $9.19M | (m) | (m) | $63.73K | (m) |
| 2013-12-31 | (m) | $1.67M | $2.37M | (m) | $2.34K | $80.02K | (m) |
| 2013-09-30 | (m) | $3.94M | $483.05K | (m) | (m) | $270.51K | (m) |
| 2013-06-30 | (m) | $2.58M | $158.41K | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | $2.23M | $692.72K | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $1.62M | $835.47K | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | $1.36M | $992.34K | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | $1.17M | $893.94K | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | $1.60M | $1.86M | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | $1.31M | $1.99M | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | $2.28M | $2.89M | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | $1.70M | $4.74M | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | $6.56M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $1.58M | $8.28M | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | $9.52M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $10.59M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $1.51M | (m) | (m) | (m) | (m) |
| 2006-10-27 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) |
| 2006-07-27 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |